Chemotherapy and neutropenia.
Myelosuppression is the most common toxicity associated with the administration of dose-intensive cytotoxic chemotherapy. The basic understanding of neutrophil biology and the physiology of chemotherapy-induced neutropenia has advanced tremendously in the past 2 decades. Concordantly, the ability to reduce the morbidity associated with neutropenia has improved. Adjunctive cytokine and progenitor cell support of hematologic recovery after myelosuppressive therapy have proved to be models of translational research and have led to novel therapeutic initiatives for patients with cancer and hematologic malignancies. In this article, fundamental aspects of neutrophil production are discussed, and the clinical development of hematopoietic cytokines active on cells of the leukocyte lineages is presented.
Kim
S K
SK
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Demetri
G D
GD
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002455:Cell Division / Q000502:physiology; D004334:Drug Administration Schedule; D006133:Growth Substances / Q000009:adverse effects; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced*; D009504:Neutrophils / Q000166:cytology; D012016:Reference Values
D000970:Antineoplastic Agents; D006133:Growth Substances